Cargando…

Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity

Antivenom immunotherapy is the mainstay of treatment for snakebite envenoming. Most parts of the world affected by snakebite envenoming depend on broad-spectrum polyspecific antivenoms that are known to contain a low content of case-specific efficacious immunoglobulins. Thus, advances in toxin-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Manson, Ernest Z., Kyama, Mutinda C., Kimani, Josephine, Bocian, Aleksandra, Hus, Konrad K., Petrilla, Vladimír, Legáth, Jaroslav, Kimotho, James H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030397/
https://www.ncbi.nlm.nih.gov/pubmed/35448894
http://dx.doi.org/10.3390/toxins14040285
_version_ 1784692129180680192
author Manson, Ernest Z.
Kyama, Mutinda C.
Kimani, Josephine
Bocian, Aleksandra
Hus, Konrad K.
Petrilla, Vladimír
Legáth, Jaroslav
Kimotho, James H.
author_facet Manson, Ernest Z.
Kyama, Mutinda C.
Kimani, Josephine
Bocian, Aleksandra
Hus, Konrad K.
Petrilla, Vladimír
Legáth, Jaroslav
Kimotho, James H.
author_sort Manson, Ernest Z.
collection PubMed
description Antivenom immunotherapy is the mainstay of treatment for snakebite envenoming. Most parts of the world affected by snakebite envenoming depend on broad-spectrum polyspecific antivenoms that are known to contain a low content of case-specific efficacious immunoglobulins. Thus, advances in toxin-specific antibodies production hold much promise in future therapeutic strategies of snakebite envenoming. We report anti-3FTxs monoclonal antibodies developed against N. ashei venom in mice. All the three test mAbs (P4G6a, P6D9a, and P6D9b) were found to be IgG antibodies, isotyped as IgG1. SDS-PAGE analysis of the test mAbs showed two major bands at approximately 55 and 29 kDa, suggestive of immunoglobulin heavy and light chain composition, respectively. The immunoaffinity-purified test mAbs demonstrated higher binding efficacy to the target antigen compared to negative control. Similarly, a cocktail of the test mAbs was found to induce a significantly higher inhibition (p-value < 0.0001) compared to two leading commercial brands of antivenoms on the Kenyan market, implying a higher specificity for the target antigen. Both the test mAbs and 3FTxs polyclonal antibodies induced comparable inhibition (p-value = 0.9029). The inhibition induced by the 3FTxs polyclonal antibodies was significantly different from the two antivenoms (p-value < 0.0001). Our results demonstrate the prospects of developing toxin-specific monoclonal-based antivenoms for snakebite immunotherapy.
format Online
Article
Text
id pubmed-9030397
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90303972022-04-23 Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity Manson, Ernest Z. Kyama, Mutinda C. Kimani, Josephine Bocian, Aleksandra Hus, Konrad K. Petrilla, Vladimír Legáth, Jaroslav Kimotho, James H. Toxins (Basel) Article Antivenom immunotherapy is the mainstay of treatment for snakebite envenoming. Most parts of the world affected by snakebite envenoming depend on broad-spectrum polyspecific antivenoms that are known to contain a low content of case-specific efficacious immunoglobulins. Thus, advances in toxin-specific antibodies production hold much promise in future therapeutic strategies of snakebite envenoming. We report anti-3FTxs monoclonal antibodies developed against N. ashei venom in mice. All the three test mAbs (P4G6a, P6D9a, and P6D9b) were found to be IgG antibodies, isotyped as IgG1. SDS-PAGE analysis of the test mAbs showed two major bands at approximately 55 and 29 kDa, suggestive of immunoglobulin heavy and light chain composition, respectively. The immunoaffinity-purified test mAbs demonstrated higher binding efficacy to the target antigen compared to negative control. Similarly, a cocktail of the test mAbs was found to induce a significantly higher inhibition (p-value < 0.0001) compared to two leading commercial brands of antivenoms on the Kenyan market, implying a higher specificity for the target antigen. Both the test mAbs and 3FTxs polyclonal antibodies induced comparable inhibition (p-value = 0.9029). The inhibition induced by the 3FTxs polyclonal antibodies was significantly different from the two antivenoms (p-value < 0.0001). Our results demonstrate the prospects of developing toxin-specific monoclonal-based antivenoms for snakebite immunotherapy. MDPI 2022-04-16 /pmc/articles/PMC9030397/ /pubmed/35448894 http://dx.doi.org/10.3390/toxins14040285 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Manson, Ernest Z.
Kyama, Mutinda C.
Kimani, Josephine
Bocian, Aleksandra
Hus, Konrad K.
Petrilla, Vladimír
Legáth, Jaroslav
Kimotho, James H.
Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title_full Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title_fullStr Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title_full_unstemmed Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title_short Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity
title_sort development and characterization of anti-naja ashei three-finger toxins (3ftxs)-specific monoclonal antibodies and evaluation of their in vitro inhibition activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030397/
https://www.ncbi.nlm.nih.gov/pubmed/35448894
http://dx.doi.org/10.3390/toxins14040285
work_keys_str_mv AT mansonernestz developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT kyamamutindac developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT kimanijosephine developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT bocianaleksandra developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT huskonradk developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT petrillavladimir developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT legathjaroslav developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity
AT kimothojamesh developmentandcharacterizationofantinajaasheithreefingertoxins3ftxsspecificmonoclonalantibodiesandevaluationoftheirinvitroinhibitionactivity